In this issue:
No additional survival benefit with bevacizumab in high-risk colon cancer
Adjuvant chemotherapy improves OS in stage III MSI-high colon cancer
Prometastatic pathway blockade with propranolol/etodolac in CRC
Adjuvant chemotherapy unnecessary in rectal cancer with pCR
Distinct molecular profile of appendiceal adenocarcinoma
Oligometastatic disease is a positive prognostic factor in mCRC
Trifluridine/tipiracil + bevacizumab in de novo mCRC
Poor prognosis in KRAS G12C mCRC
Age impacts outcomes of upfront chemotherapy in mCRC
Next-generation sequencing in mCRC
Please login below to download this issue (PDF)